CAJ | 학술논문

目的观察应用盐酸美金刚治疗中重度老年性痴呆患者的疗效.方法收集79例中重度老年性痴呆患者,口服盐酸美金刚12周.采用自身对照法分别在治疗前、治疗后第4周、第8周、第12周采用简易智能精神状态量表(MMSE)、日常生活功能量表(ADL)、临床痴呆程度量表(CDR)对患者进行评估,运用SPSS 13.0统计软件,统计学分析各组数据以均数±标准差((x)±s)表示,采用f检验,P＜ 0.05为差异具有统计学意义.结果与治疗前相比,治疗后第4周MMSE评分显著增高(t=7.151,P＜0.01),但ADL、CDR评分变化不明显(f=1.926、1.56,P＞0.05);治疗后第8、12周MMSE评分有显著提高(t=1 1.24、17.16,P＜0.01),ADL评分改善(t=7.836、25.76,P＜ 0.01),CDR评分减低(t=7.266、10.36,P＜ 0.01).治疗过程中患者未出现严重不良反应.结论盐酸美金刚治疗中重度老年性痴呆疗效可靠,治疗后第8周即可显著改善其认知及行为能力,且安全性好.
목적 관찰응용염산미금강치료중중도노년성치태환자적료효.방법 수집79례중중도노년성치태환자,구복염산미금강12주.채용자신대조법분별재치료전、치료후제4주、제8주、제12주채용간역지능정신상태량표(MMSE)、일상생활공능량표(ADL)、림상치태정도량표(CDR)대환자진행평고,운용SPSS 13.0통계연건,통계학분석각조수거이균수±표준차((x)±s)표시,채용f검험,P＜ 0.05위차이구유통계학의의.결과 여치료전상비,치료후제4주MMSE평분현저증고(t=7.151,P＜0.01),단ADL、CDR평분변화불명현(f=1.926、1.56,P＞0.05);치료후제8、12주MMSE평분유현저제고(t=1 1.24、17.16,P＜0.01),ADL평분개선(t=7.836、25.76,P＜ 0.01),CDR평분감저(t=7.266、10.36,P＜ 0.01).치료과정중환자미출현엄중불량반응.결론 염산미금강치료중중도노년성치태료효가고,치료후제8주즉가현저개선기인지급행위능력,차안전성호.
Objective To observe the effect and safety of Memantine Hydrochloride in the treatment of moderate to severe Alzheimer's disease.Methods 79 cases of moderate to severe Alzheimer's disease in our hospital from January 2011 to March 2013 were treated with Memantine Hydrochloride for 12 weeks.The score of Mini-Mental State Examination (MMSE),Activities of Daily Living (ADL) and Clinical Dementia Rating (CDR) was recorded and compared before and 4,8,12 weeks after treatment.Used t test,P ＜ 0.05meant significant difference.Results 4 weeks after treatment,MMSE increased (t =7.151,P ＜ 0.01),ADL decreased slightly (t =1.926,P ＞ 0.05),CDR didn't change significantly (t =1.56,P ＞ 0.05); 8 and 12weeks after treatment,MMSE increased significantly (t =11.24,17.16,P ＜ 0.01),ADL and CDR decreased significantly (P ＜ 0.01).No serious adverse reactions occurred in the treatment.Conclusion Memantine Hydrochloride in the treatment of moderate to severe Alzheimer's disease is safe and effective,and the longer patients accept the treatment,the more obvious the effect is.